Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor with Robust In Vivo Activity

On May 15, 2020 Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, reported the identification of an HPK1 inhibitor with highly potent and selective anti-tumor activity in preclinical models (Press release, Nimbus Therapeutics, MAY 15, 2020, View Source [SID1234558110]). The data will be presented at the AACR (Free AACR Whitepaper) Virtual Annual Meeting II, June 22-24, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HPK1 (hematopoietic progenitor kinase 1) is a highly valued target in immuno-oncology due to its role as a regulator of both T cell and dendritic cell activity. However, a key challenge for development of small molecules acting on HPK1 has been to achieve selectivity against other T cell kinases and MAP4K family members. Nimbus utilized its unique structure-based drug discovery engine to identify multiple potent and selective small molecule inhibitors of HPK1. One of these molecules, advanced to in vivo testing, has high selectivity against T cell-specific kinases and kinases in the MAP4K family and exhibits promising activation of human T cells and B cells. In a mouse syngeneic tumor model, oral administration of the HPK1 inhibitor completely eliminated HPK1’s phosphorylation of the T cell receptor, enhanced inflammatory cytokine production, and demonstrated robust tumor growth inhibition.

"We’re excited to pull back the curtain on Nimbus’ HPK1 program and share some of the progress we’ve made against a target that has evaded so many others’ efforts," said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. "Nimbus’ unparalleled expertise in structure-based drug discovery allowed us to chart an entirely new approach to inhibiting HPK1. In addition, we have recently leveraged this approach to generate small molecules against a range of promising new targets, and we look forward to sharing details on these programs in the coming weeks."

"These data support the potential of our HPK1 inhibitor to alter the tumor microenvironment to halt cancer’s immune evasion, which we think could be a powerful tool in today’s immuno-oncology arsenal," said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. "We are advancing this program into IND-enabling studies, with the goal of entering the clinic next year, and ultimately providing a new therapeutic approach to address the large unmet need among patients with cancer."

HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients

On May 15, 2020 HiFiBiO Therapeutics reported that have generated preclinical data packages for novel monoclonal antibodies that demonstrate favorable clinical development profiles as new cancer immunotherapeutic options (Press release, HiFiBiO Therapeutics, MAY 15, 2020, View Source [SID1234558131]). The team will present highlights in three poster sessions at the forthcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, June 22-24, 2020. Taken together, these three programs from the HiFiBiO Therapeutics pipeline are evidence of the maturation of the company’s unique and comprehensive capabilities to uncover disease mechanisms and indications at the single-cell level; apply a deep understanding of immune system biology to select antibodies that present the best prospects for clinical development; and match these high-quality antibodies to the patients who are most likely to derive benefit.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to have the opportunity to present our work to the oncology research community at AACR (Free AACR Whitepaper) and to share our innovative approach to transform the drug discovery and development paradigm by combining a deep understanding of immune-modulation with a world-leading single-cell platform and integrated analytics. By applying this approach over the past two and a half years, we have built a sustainable pipeline with high-quality candidates moving rapidly towards clinical studies," said Liang Schweizer, PhD, President and CEO of HiFiBiO Therapeutics.

The three HiFiBiO Therapeutics pipeline programs being presented at the AACR (Free AACR Whitepaper) meeting are:

HFB3010 (OX40)

HFB301001 is a novel, fully human IgG1 class OX-40 agonistic antibody with an optimized pharmacological profile. In contrast to previous anti-OX-40 antibodies, the agonistic activity of HFB301001 is further enhanced in the presence of the endogenous ligand OX-40L, does not result in reduced expression of OX-40 on T cells, and leads to superior anti-tumor activity in a human OX-40 knock-in mouse model compared to a benchmark antibody. Applying innovative biomarker strategy by leveraging its cutting-edge single-cell platform, HiFiBiO Therapeutics is developing the HFB301001 clinical candidate targeting certain patient populations which confer sensitivity towards treatment.

HFB2003 (TNFR2)

HiFiBiO Therapeutics has discovered and is pursuing the development of a first-in-class anti-TNFR2 monoclonal antibody capable of co-stimulating T cell proliferation and inducing strong in vivo anti-tumor immunity. In tumors, TNFR2 is expressed on activated and exhausted T cells. Targeting TNFR2 has the potential to enhance anti-tumor immunity by stimulating T-cell activation and proliferation in the tumor microenvironment. HiFiBiO’s CelliGO platform enabled the identification of diverse anti-TNFR2 antibodies that target different epitopes of the receptor. The candidate HFB200301 preferentially binds to TCR-activated primary CD8 and CD4 T cells as compared to unstimulated T cells and enhances CD3/CD28-induced activation and proliferation. Single agent anti-tumor activity comparable to anti-PD-1 was observed in several mouse tumor models at well-tolerated doses. An acute NHP exploratory study revealed no safety concerns for this novel mechanism. The clinical candidate HFB200301 has favorable developability and PK profiles and is currently at CMC development stage.

HFB2009 (Gal-9)

Galactoside-binding lectin Galectin 9 (Gal-9) is a key pleiotropic immunosuppressive modulator present in the tumor microenvironment. High Gal-9 expression has been reported in several cancer types including hematological malignancies such as AML and ALL, as well as in multiple solid tumors. Neutralization of Gal-9 has the potential to enhance anti-tumor immune response in the tumor micro-environment. HiFiBiO Therapeutics has discovered and is pursuing the development of HFB200902, an anti-Gal-9 neutralizing antibody with first-in-class potential in AML and solid tumors. HFB200902 blocks the interaction of Gal-9 with TIM3 and CD44, two receptors that have been described to mediate Gal-9-immunosuppressive signals in effector and regulatory T cells. As a result, HFB200902 inhibits Gal-9 induced Th1 cell apoptosis and Treg expansion. Anti-tumor activity and increased survival were observed as single agent and in combination with anti-PD1 in a syngeneic tumor model.

HiFiBiO Therapeutics will take innovative approaches to clinical development of these and other candidates in its pipeline, by pairing these novel antibody candidates with patient stratification biomarkers identified using the company’s proprietary DIS approach. This enables the company’s scientists to analyze individual patient cell samples to understand the complex functions and heterogeneity in immune system characteristics and responses among different patient groups, and to define predictive biomarkers that can be used to match the therapeutics to those patients who will most likely benefit from them.

"The challenges of achieving clinical success for immunotherapies are often related to the complex biology of the tumor microenvironment. Our pipeline focuses on targets with roles on multiple immune cell types, and our development strategy hinges on combining candidates with novel biomarkers to ensure a higher probability of clinical success," commented Francisco Adrian, Senior Vice President of Global Research, HiFiBiO Therapeutics.

"Our single-cell technology paired with our unique data analysis capability enables us to identify novel biomarkers derived from particular immune cell types and mechanisms. Using this approach, we should be able to stratify patients using their profiled genotype and phenotype, which predict sensitivity or resistance to treatment with our antibody candidates," said Andreas Raue, Senior Director of Drug Intelligent Science, HiFiBiO Therapeutics.

Registration for the virtual meeting is being offered by AACR (Free AACR Whitepaper) free of charge; more information is available at AACR (Free AACR Whitepaper) Virtual Annual Meeting II.

Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor With Robust In Vivo Activity

On May 15, 2020 Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, reported the identification of an HPK1 inhibitor with highly potent and selective anti-tumor activity in preclinical models (Press release, Nimbus Therapeutics, MAY 15, 2020, View Source [SID1234558157]). The data will be presented at the AACR (Free AACR Whitepaper) Virtual Annual Meeting II, June 22-24, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HPK1 (hematopoietic progenitor kinase 1) is a highly valued target in immuno-oncology due to its role as a regulator of both T cell and dendritic cell activity. However, a key challenge for development of small molecules acting on HPK1 has been to achieve selectivity against other T cell kinases and MAP4K family members. Nimbus utilized its unique structure-based drug discovery engine to identify multiple potent and selective small molecule inhibitors of HPK1. One of these molecules, advanced to in vivo testing, has high selectivity against T cell-specific kinases and kinases in the MAP4K family and exhibits promising activation of human T cells and B cells. In a mouse syngeneic tumor model, oral administration of the HPK1 inhibitor completely eliminated HPK1’s phosphorylation of the T cell receptor, enhanced inflammatory cytokine production, and demonstrated robust tumor growth inhibition.

"We’re excited to pull back the curtain on Nimbus’ HPK1 program and share some of the progress we’ve made against a target that has evaded so many others’ efforts," said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. "Nimbus’ unparalleled expertise in structure-based drug discovery allowed us to chart an entirely new approach to inhibiting HPK1. In addition, we have recently leveraged this approach to generate small molecules against a range of promising new targets, and we look forward to sharing details on these programs in the coming weeks."

"These data support the potential of our HPK1 inhibitor to alter the tumor microenvironment to halt cancer’s immune evasion, which we think could be a powerful tool in today’s immuno-oncology arsenal," said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. "We are advancing this program into IND-enabling studies, with the goal of entering the clinic next year, and ultimately providing a new therapeutic approach to address the large unmet need among patients with cancer."

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

On May 15, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that data from two studies investigating innate cell engagers developed from its fit-for-purpose ROCK platform have been accepted for e-poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II being held on June 22-24, 2020 (Press release, Affimed, MAY 15, 2020, View Source [SID1234558173]). Affimed researchers served as authors on abstract #5659 and co-authors on abstract #6987 with scientific collaborators from Genentech, a member of the Roche Group, on the respective abstracts that include the following:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies

Abstract: 5659

Authors: Uwe Reusch, Michael Damrat, Susanne Wingert, Stefan H.J. Knackmuss, Thomas Mueller, Ivica Fucek, Ute Schniegler-Mattox, Kristina Ellwanger, Torsten Haneke, Andras Strassz, Wolfgang Fischer, Erich Rajkovic, Michael Tesar. Affimed GmbH, Heidelberg, Germany

Poster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.

Title: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma

Abstract: 6987

Authors: Satoko Kakiuchi-Kiyota, Melissa Schutten, Adeyemi O. Adedeji, Hao Cai, Robert Hendricks, Luna Liu, Sivan Cohen, Aaron Fullerton, Nicholas Corr, Lanlan Yu, Denise de Almeida-Nagata, Shelly Zhong, Michael Dillon, Christoph Spiess, Steve Leong, Bing Zheng. Genentech Inc.; Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Thorsten Ross. Affimed; Andy Polson, Ayse Meric Ovacik. Genentech Inc.

Poster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.

More details about the programs for the AACR (Free AACR Whitepaper) Virtual Annual Meeting II are available online at www.aacr.org.

Conference Call Information

Affimed will host a live teleconference today, Friday May 15th at 8am Eastern to discuss the abstracts and recent corporate developments. The teleconference details will be available in the "Webcasts" section on the "Investors" page of the Affimed website at View Source, and a replay of the teleconference will be accessible at the same link for 30 days following the call.

IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program

On May 15, 2020 IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics (Press release, Ideaya Biosciences, MAY 15, 2020, View Source [SID1234558191]). The company announced publication today of abstracts at the 2020 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The IDEAYA abstracts were posted online by AACR (Free AACR Whitepaper) (View Source) in advance of the AACR (Free AACR Whitepaper) Virtual Annual Meeting II, which will be held on June 22-24, 2020:

Title: "Analysis of drug combinations with the PKC inhibitor IDE196 support dual MEK and PKC inhibition as a rational combination in metastatic uveal melanoma" (Author: Christian Frey)
Title: "MAT2A Inhibitors decrease growth, increase senescence and p53 stability in MTAP-deleted cancer cells" (Author: Neil Bhola)
Title: "In vitro and in vivo characterization of novel MAT2A allosteric inhibitors" (Author: Zhonghua Pei)
IDE196 is a potent and selective protein kinase C (PKC) inhibitor being evaluated in an ongoing Phase 1/2 tumor-agnostic clinical trial in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) hotspot mutations. IDEAYA is currently enrolling into a Phase 2 monotherapy expansion arm for patients with such GNAQ/11 mutant tumors, including Cutaneous Melanoma, and recently completed enrollment into a Phase 1 monotherapy arm for patients with Metastatic Uveal Melanoma. IDEAYA is preparing to evaluate the clinical combination of IDE196 and binimetinib, a MEK inhibitor, in a combination arm initiating in mid-2020 for patients with such GNAQ/11 hotspot mutations.

"We believe that IDE196 presents multiple opportunities for being impactful for patients and creating value. The preclinical combination data with IDE196 and MEK inhibitor being presented at AACR (Free AACR Whitepaper) helps guide our clinical development strategy, and demonstrates our commitment to validating these opportunities," said Yujiro S. Hata, Chief Executive Officer and President at IDEAYA Biosciences.

IDEAYA’s most advanced synthetic lethality program is targeting methionine adenosyltransferase II alpha (MAT2A). IDEAYA plans to develop a MAT2A inhibitor for patients having solid tumors with methylthioadenosine phosphorylase (MTAP) gene deletion, which occurs in approximately 15% of all solid tumors. MTAP-null tumor cells have been shown to be more dependent on the activity of MAT2A, resulting in synthetic lethality when MAT2A is pharmacologically inhibited.

"We are building a leading company in synthetic lethality – an emerging area of precision medicine oncology, with active ongoing research across multiple targets, including MAT2A, Pol theta, Werner helicase and PARG. Our MAT2A program presents a potential opportunity to be best in class in the molecularly-defined patient population of MTAP-deletion. We recently selected a differentiated MAT2A inhibitor lead compound and are on track for an IND submission to the FDA in the fourth quarter of 2020. We look forward to sharing additional data on this molecule as we advance this program," said Dr. Michael Dillon, Ph.D., Senior Vice President, Chief Scientific Officer and Head of Research at IDEAYA Biosciences.